These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22142541)

  • 1. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
    Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
    Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
    J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
    Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V
    Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
    Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
    Fernandez MC; Escribano A; Mateo AI; Parthasarathy S; Martin de la Nava EM; Wang X; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel A; Sweetana SA; Cannady EA; Stephenson G; Frank S; Mantlo NB
    Bioorg Med Chem Lett; 2012 May; 22(9):3056-62. PubMed ID: 22497761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
    Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a novel class of biphenyl CETP inhibitors.
    Lu Z; Napolitano JB; Theberge A; Ali A; Hammond ML; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7469-72. PubMed ID: 21041082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy.
    Sweis RF; Hunt JA; Sinclair PJ; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Anderson MS
    Bioorg Med Chem Lett; 2011 May; 21(9):2597-600. PubMed ID: 21398121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromanol derivatives--a novel class of CETP inhibitors.
    Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H
    Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Bergman AJ; Jin B; Fallon M; Cote J; Van Hoydonck P; Laethem T; Gendrano IN; Van Dyck K; Hilliard D; Laterza O; Snyder K; Chavez-Eng C; Lutz R; Chen J; Bloomfield DM; De Smet M; Van Bortel LM; Gutierrez M; Al-Huniti N; Dykstra K; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
    [No Abstract]   [Full Text] [Related]  

  • 17. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DEFINE study: a bright future for CETP inhibitors?
    Katsiki N; Athyros VG; Mikhailidis DP
    Expert Opin Investig Drugs; 2011 Mar; 20(3):311-4. PubMed ID: 21235422
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.